165 related articles for article (PubMed ID: 21896578)
21. HER2 gene amplification in patients with breast cancer with equivocal IHC results.
Meijer SL; Wesseling J; Smit VT; Nederlof PM; Hooijer GK; Ruijter H; Arends JW; Kliffen M; van Gorp JM; Sterk L; van de Vijver MJ
J Clin Pathol; 2011 Dec; 64(12):1069-72. PubMed ID: 21836036
[TBL] [Abstract][Full Text] [Related]
22. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY; Oh YL
Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
[TBL] [Abstract][Full Text] [Related]
23. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
Bai YF; Ren GP; Wang B; Teng LS; Liu X
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
[TBL] [Abstract][Full Text] [Related]
24. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
[TBL] [Abstract][Full Text] [Related]
25. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
26. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
27. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
Dandachi N; Dietze O; Hauser-Kronberger C
Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
[TBL] [Abstract][Full Text] [Related]
29. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
30. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
31. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
[TBL] [Abstract][Full Text] [Related]
33. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
34. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.
McCaughan H; Um I; Langdon SP; Harrison DJ; Faratian D
J Clin Pathol; 2012 Jul; 65(7):670-1; author reply 671-2. PubMed ID: 22412045
[No Abstract] [Full Text] [Related]
35. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Hauser-Kronberger C; Dandachi N
J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
[TBL] [Abstract][Full Text] [Related]
37. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
[TBL] [Abstract][Full Text] [Related]
38. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
[TBL] [Abstract][Full Text] [Related]
39. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y; Sweet W; Duh YJ; Greenfield L; Tarco E; Trivedi S; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Aug; 132(2):228-36. PubMed ID: 19605817
[TBL] [Abstract][Full Text] [Related]
40. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
